P2.13-40 ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1435
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial

Oncotarget
Oncology
2017English

A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer

Investigational New Drugs
OncologyPharmacology
2014English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-42 Phase II Trial Allowed Surgery After Induction Chemotherapy of CBDCA+PTX, Bevacizumab in Patients With Stages IIIA-IV Nonsquamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MINI01.02: Response and Plasma Genotyping From Phase I/Ii Trial of Ensartinib (X-396) in Patients (Pts) With ALK+ NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

Oncologist
Cancer ResearchMedicineOncology
2015English

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Time-Course Observation of Auditory Brainstem Response in Comatose Patients.

AUDIOLOGY JAPAN
1986English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy